Infertile offspring is a common pharma induced mutation, so along with all the other "colour me shocked" responses to mRNA, this is also no shocker.
DES had a similar outcome. Prescribed to prevent problems in pregnancy for 40 years, the damage to offspring took a long time to correlate to the drug. It also carcinogenic. It also didn't work.
Diethylstilbestrol (DES) is a synthetic form of the female hormone estrogen. It was prescribed to pregnant women between 1940 and 1971 to prevent miscarriage, premature labor, and related complications of pregnancy (1). The use of DES declined after studies in the 1950s showed that it was not effective in preventing these problems, although it continued to be used to stop lactation, for emergency contraception, and to treat menopausal symptoms in women.
In 1971, researchers linked prenatal (while in the womb, or in utero) DES exposure to a type of cancer of the cervix and vagina called clear cell adenocarcinoma in a small group of women. Soon after, the Food and Drug Administration (FDA) notified health care providers throughout the country that DES should not be prescribed to pregnant women. The drug continued to be prescribed to pregnant women in Europe until 1978.
DES is now known to be an endocrine-disrupting chemical, one of a number of substances that interfere with the endocrine system to potentially cause cancer, birth defects, and other developmental abnormalities.
Infertile offspring is a common pharma induced mutation, so along with all the other "colour me shocked" responses to mRNA, this is also no shocker.
DES had a similar outcome. Prescribed to prevent problems in pregnancy for 40 years, the damage to offspring took a long time to correlate to the drug. It also carcinogenic. It also didn't work.
Trust the science™
https://www.niehs.nih.gov/health/topics/agents/endocrine/index.cfm
https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/des-fact-sheet
Diethylstilbestrol (DES) is a synthetic form of the female hormone estrogen. It was prescribed to pregnant women between 1940 and 1971 to prevent miscarriage, premature labor, and related complications of pregnancy (1). The use of DES declined after studies in the 1950s showed that it was not effective in preventing these problems, although it continued to be used to stop lactation, for emergency contraception, and to treat menopausal symptoms in women.
In 1971, researchers linked prenatal (while in the womb, or in utero) DES exposure to a type of cancer of the cervix and vagina called clear cell adenocarcinoma in a small group of women. Soon after, the Food and Drug Administration (FDA) notified health care providers throughout the country that DES should not be prescribed to pregnant women. The drug continued to be prescribed to pregnant women in Europe until 1978.
DES is now known to be an endocrine-disrupting chemical, one of a number of substances that interfere with the endocrine system to potentially cause cancer, birth defects, and other developmental abnormalities.